CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

First-line CAR-T-cell consolidation after an abbreviated induction with 2 cycles of Rituximab and Ibrutinib prior to CAR-T-cell treatment and followed by 6 months of maintenance with Ibrutinib in patients with high risk MCL.

Trial Details

NCT ID
NCT06482684
Phase
PHASE2
Sponsor
Christian Schmidt, MD
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • KTE-X19
  • Ibrutinib
Locations (sample)
  • Mainz, Germany|49.98185,8.28008
  • Munich, Germany|48.13743,11.57549

Key Eligibility Criteria

  • Histologically confirmed diagnosis of MCL according to WHO classification, with documentation of either overexpression of cyclin D1 or presence of …
  • At least one High Risk MCL - feature as defined as I. MIPI-c high intermediate (HI) or high (H) risk (i.e. high risk MIPI irrespective of Ki-67 or …
  • No prior treatment for MCL
  • Stage II-IV (Ann Arbor)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →